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ABSTRACT 
One of the proteinase inhibitors that has been studied in 
great detail is human alpha-1-proteinase inhibitor (alpha-1-
PI). Alpha-1-PI is a single chain glycoprotein with a 
molecular weight of 51,000. Although it inhibits serine 
proteinases such as trypsin, chymotrypsin and elastase, its 
target enzyme appears to be neutrophil elastase. 
The objective of this study is to investigate the 
kinetic stability of alpha-1-PI in the acidic and alkaline pH 
ranges. Alpha-1-PI was isolated from discarded human blood 
and subjected to 50-80% salt fractionation. It was further 
purified by DEAE-cellulose chromatography followed by 
chromatography on Con A Sepharose 4B column. The preparation 
Wcis found to be homogeneous both with respect to charge and 
size as indicated by analytical gel chromatography and sodium 
dodecyl sulphate polyacrylamide gel electrophoresis under 
reducing and non-reducing conditions. 
The purified alpha-1-PI was found to be sensitive to pH 
at extreme values. At neutral pH, the inhibitor did not lose 
activity for 12 hours at 30°C. In acidic pH range below 5.0, 
precipitation of the inhibitor occurred. This precipitation 
was reversed by 8M urea without regain of inhibitory 
activity. Above pH 10.0 there was a measurable inactivation 
of inhibitor. At pH 11.0, the time course of inactivation 
was investigated at four temperatures namely 25°C, 30°C, 35°C 
and 40°C. The buffer used was lOmM sodium carbonate buffer. 
pH 11.0 containing 0.15M NaCl. The inactivation process 
followed first order kinetics whence first order rate 
constant, k, was determined at four temperatures. From an 
Arrhenius plot of Ink versus 1/T, the activation energy for 
inactivation was computed to be 18.74 kcal/mole. As judged 
from the value of activation energy, alkaline inactivation of 
alpha-1-PI at pH 11.0 does not appear to be accompanied by 
major conformational changes in the protein. This is clear 
from our result on circular dichroic spectra of alpha-1-PI 
at pH 8.0 and pH 11.0 in far UV region. 
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INTRODUCTION 
Human plasma contains a number of proteinase inhibitors 
which together represent 10% of the total plasma 
proteins (Travis & Salvesen, 1983). Protein proteinases 
are an important group of proteins capable of inhibiting 
the activity of proteolytic enzymes. They are ubiquitous 
and are found in all forms of life (Laskowski & Kato, 
1980; Travis & Salvesen, 1983). Their primary function 
is to restrict and control the action of proteinases. 
These inhibitors act on four major classes of 
proteinases, viz., serine proteinases, cysteine 
proteinases, acid proteinases and metallo proteinases 
(Laskowski, 1986). Serine proteinase inhibitors 
(serpins) have been most extensively studied. Based 
upon amino acid sequence and disulphide bond topology, 
serpins have been classified into thirteen different 
families. They are listed in Table I. The three 
dimensional structure of inhibitors belonging to ten of 
the thirteen different classes has been determined 
either by X-ray crystallography or by 2D NMR 
spectroscopy (Bode, et al., 1985; Bode, et al., 1987; 
Huber & Carell, 1989). 
Inhibitors of serine proteinases are known to be 
involved in phagocytosis, coagulation, complement 
activation and fibrinolysis. Quite often, the primary 
function of serpins is regulation of proteolytic events 
TABLE I 
FAMILIES OF PROTEIN INHIBITORS OF SERINE PROTEINASES 
Animals 
1 Bovine pancreatic t rypsin inh ib i to r (Kunitz) 
family^ 
2. Pancreatic secretory trypsin inhibitor (Kazal) 
family^ 
3. Ascaris inhibitor family^. 
4. Serpin family (mechanistically distinct)*^ 
5. Hirudin family^ 
Plants 
6. Soyabean trypsin inhibitor (Kunitz) family® 
7. Soyabean proteinase inhibitor (Bowman Birk) family*^  
8. Potato 1 family^ 
9. Potato 2 family^ 
10. Barley trypsin inhibitor family" 
11. Squash inhibitor family-"-
Microbial 
12. Streptomyces subtilisin inhibitor (SSI) family^ 
13. Other families 
a. Laskowski (1986) . 
b. Laskowski, et al. (1980). 
c. Babin, et al. (1984). 
d. Carrell and Travis, (1985). 
e. Hejgaard, et al. (1983). 
f. Graham, et al. (1985a). 
g. Graham, et al. (1985b). 
h. Odani, et al. (1983); Campas and Richardson (1983); 
Mahoney, et al (1984). 
i. Wieczorek, et al. (1985); Joubert (1984). 
associated with the number of biochemical pathways (see 
Fig. 1). The major examples of serpins are alpha-1-
proteinase inhibitor (alpha-1-PI) or alpha-1-
antitrypsin, alpha-1-antichymotrypsin, antithrombin III 
and alpha-antiplasmin. Human alpha-1-PI has been the 
subject of extensive investigations primarily because of 
its pathological importance (Erikson, 1965). The 
inhibitor is primarily synthesised in liver but it has 
been identified histochemically in monocytes and 
macrophages. Alpha-1-PI is primarily a defence protein 
v^ hose function is to protect the tissues from attack by 
released proteolytic enzymes. 
The alpha-1-PI gene comprises seven exons and six 
introns over 12.2 kb of chromosome 14 (Long, et al., 
1984; Rabin, et al., 1986; Shen, et al., 1987) and is 
highly pleomorphic. As many as 75 alleles of the 
inhibitor have been identified so far. Besides normal 
alpha-l-PI alleles, there are deficient alleles that are 
associated with low serum levels of the inhibitor. The 
deficient alleles Z, S and Mprocida ^^ "^ ® been studied 
more extensively than the others (Travis & Salvesen, 
1983; Curiel, et al., 1989; Takahashi, et al., 1988). 
The inhibitor competitively inhibits the target 
enzyme which binds a substrate-like region in the 
inhibitor (Laskowski & Kato, 1980) in the molar ratio of 
1:1. Most of the serine proteinase-directed inhibitors 
react with cognate enzymes according to a common, 
substrate-like standard mechanism (Laskowski & Kato, 
(1) Extracellularmatrix remodeling 
(14) Blood coagulation 
(13) Complement cascade 
(12) Fibrinolysis 
(11) Protein folding 
(10) Cell migration 
(9) Cell differentation 
SERPEV 
(2) Prohormone conversion 
(3) Intracellular proteoh sis 
(4) Blood pressure 
(5) Tumour suppression 
(6) Harmone Transportation 
(7) Viral or parasite 
Pathogenicity 
(8) Modulation of inflammatory 
response 
Fig.l : Multiple regulatory functions of serpins 
(Potempa. etal., 1994). 
1980; Huber & Bode, 1978). The target enzyme binds to 
the inhibitor through the amino acid residue PI at or 
near the active site region. The peptide bond between 
P-, and P-,' known as reactive site peptide bond, is 
hydrolyzed during the complex formation between the 
inhibitor and enzyme with Kcat/Km of 10^ -^10° M"-^  sec"-'" 
(Travis & Salvesen, 1983). 
The rate constants for the association of various 
proteinases with human alpha-1-PI are listed in Table II 
(Travis, et al., 1985). As it is apparent from the 
values of association rate constants, the significant 
role of inhibitor is the regulation of proteinase 
activity of neutrophil elastase. 
Primary structure of alpha-l-PI 
Human alpha-1-PI is a protein consisting of single 
polypeptide chain containing 394 amino acid residues. 
The amino acid sequence was deduced both by protein 
sequencing methods (Carrell, et al., 1979; Carrell, et 
al., 1982) and by the cloning and sequencing of cDNA 
for the inhibitor from human and baboon. (Kurachi, et 
al., 1981). The amino acid sequence of alpha-1-PI is 
depicted in Fig. 2. Table III shows the amino acid 
composition of inhibitor as deduced from the sequence of 
amino acid residues. The number of acidic amino acid 
residues is 56 ( 24 Asp and 33 Glu) which is greater than 
that of basic amino acid residues (54; 13 His., 34 lys 
TABLE II 
RATE OF ASSOCIATION OF PROTEINASES WITH HUMAN ALPHA-1-
PROTEINASE INHIBITOR 
S.No. Enzymes Rate constant^ 
(M"-"- sec"^) 
1. Neutrophil elastase 6.5 X lo"^  
2. Pancreatic elastase 1.0 X 10^ 
3. Cathepsin G 4.1 X 10^ 
4. Pancreatic trypsin 4.2 X lO"^  
5. Factor Xa 2.0 X 10^ 
6. Plasmin 1.9 X 10^ 
7. Thrombin 4.8 X 10^ 
a. Travis, et al. , (1985). 
F i g . 2 : AMINO ACID SEQUENCE OF HUMAN ALPHA 1 PROTEINASE INHIBITOR 
TABLE III 
AMINO ACID COMPOSITION OF HUMAN ALPHA-1-PROTEINASE 
INHIBIITOR 
S.No. Amino acid Number of residues^ 
27 
6 
2 
24 
33 
19 
18 
13 
34 
7 
21 
31 
9 
1 
22 
17 
24 
24 
45 
19 
Total 394 
a. Deduced from amino acid sequence {Carrell, et al., 
1982) . 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
11. 
12. 
13. 
14. 
15. 
16. 
17. 
18. 
19. 
20. 
Phenylalanine 
Tyrosine 
Tryptophan 
Aspartic acid 
Glutamic acid 
Asparagine 
Glutamine 
Histidine 
Lysine 
Arginine 
Serine 
Threonine 
Methionine 
Cysteine 
Glycine 
Proline 
Alanine 
Valine 
Leucine 
Isoleucine 
and 7 Arg) as a result of which the inhibitor is 
expected to possess a net negative charge at the 
physiological pH. The polypeptide chain consists of only 
one cysteine residue at position 232 which is flanked by 
His-231 and Lys-233 and is generally linked with 
glutathione or immunoglobulins (Laurell & Jeppson, 
1975) . In the native form the sulfydryl group exists 
in the reduced form which protects the inhibitor from 
inactivation by oxidants. The hydrophobic amino acids, 
namely alanine, valine, leucine, isoleucine, 
phenylalanine, tyrosine, tryptophan and methione, 
constitute 40% of the total amino acid residues in the 
inhibitor. Characterisation of various single amino acid 
substitutions at position 51 suggests that volume and 
flexibility of hydrophobic side chain at the site are 
critical for enhancing the stability of alpha-l-PI 
(Kwon, et al., 1994). It was reported that proline at 
position 391 as well as the nine amino acid-conserved 
sequence near the carboxyl terminal is critical for the 
efficient secretion of alpha-l-PI (Brodbeck & Brown, 
1994) . 
The reactive site of alpha-l-PI is located near 
the C-terminal region around Met-358. The short segment 
of sequence around Met-358 is given in Fig. 3. There are 
mutants of alpha-l-PI where only the residue at PI is 
replaced by Val (Valine mutant) or Arg (Pittsburg 
mutant) (Carrell & Travis, 1985) and the residues at 
positions P2, PI', P2', P3' and P4' remain the same as 
10 
^4 ^3 ^2 Pi Pi ^2 P3 P4 
. MET-PHE-LEU-GLU-ALA-ILE-PRO-MET-SER-ILE-PRO-PRO-GLU-VAL-LYS 
Fig. 3 : Amino acid sequence around active site residue 
Met-358 in human alpha-1-proteinase inhibitor. 
11 
in the normal alpha-l-PI. Substitution of Val-358 by 
similar hydrophobic amino acid residue, such as Ala, had 
no effect on the inhibitory activity of Valine mutant 
(Matheson, et al., 1986). However, Val mutant is more 
sensitive to heat inactivation than the normal alpha-l-
PI (Travis, et al., 1985). 
Physico chemical properties of alpha-l-PI 
Alpha-l-PI is a single chain glycoprotein 
containing 11-13% carbohydrate. Its physico chemical 
properties are listed in Table IV. The molecular weight 
and the sedimentation coefficient S20 w values suggest a 
globular conformation of the inhibitor. The three 
oligosaccharide chains are linked to Asn-46, Asn-83 and 
Asn-247 (Travis & Salvesen, 1983; Carrell & Travis, 
1985; Takahara & Sinohara, 1982) . Interestingly the 
recombinant alpha-l-PI, devoid of carbohydrate, differs 
from the normal inhibitor in folding and refolding 
reactions. With the recombinant inhibitor, marked 
aggregation was observed during refolding reaction 
(Powell Sc Pain, 1992) . 
Structure of alpha-l-PI 
Structure of alpha-l-PI modified at the reactive 
site peptide bond Met-358--Ser-359 has been analysed by 
Loebermann, et al., (1984) by X-ray diffraction at 3A° 
resolution. The dimensions of the molecule are 67A°x 
32A° X 32A°. The polypeptide chain is arranged almost 
12 
TABLE IV 
PHYSICO-CHEMICAL PROPERTIES OF HUMAN ALPHA-1-PROTENAISE 
INHIBITOR 
S.No. Property Value 
1. 
(i) 
(ii) 
2. 
3. 
4. 
5. 
6. 
Molecular Weight 
(KDa):-
SDS- PAGE 
Sedimentation 
equilibrium 
Carbohydrate 
No.of polypeptide 
chain 
^"""^icm ^^ •^^^ ^^ 
Sedimentation 
coefficient, S20 W 
Partial specific 
volume, V2, ml/gm. 
49-52^ 
49.7,^ 54^ 
13.4^,11.2^ 
1^ 
5-5.3^ 
3.15^, 3.65^ 
0.725^ 
a. Travis & Salvesen (1983); Musiani & Tomasi, Jr.(1976); 
Pannell, et al., (1974). 
b. Takahara & Sinohara (1982); Takahara & Sinohara (1983); 
13 
exclusively in well defined secondary structure elements 
that are documented in Table V and the stereoscopic 
drawing of the secondary structural elements of alpha-1-
PI is shown in Fig. 4 
The first 160 amino acid residues of the 
inhibitor in the N-terminal region predominantly form «-
helix, whereas the residues in the C-terminal region 
containing reactive site peptide bond prefer to exist in 
6-structure. The inhibitor possesses a highly ordered 
structure with 40% B -sheet and 32% (X.-helix. Bruch, 
et al., (1988), obtained similar values for c<-helix 
(35%) and ^ -structure (44%). 
Evidently the dominant element is the large Sheet 
A consisting of six strands arranged antiparallely 
except strand l which is parallel to strand 2. Sheet B 
is also formed from six strands arranged antiparallely. 
Sheet B is approximately perpendicular to sheet A. 
Sheet C consists of 3 strands. Segment 202 to 223 forms 
a strongly twisted double stranded antiparallel ladder. 
Sheet A is relatively flat, Sheet B is strongly twisted, 
Sheet C has also a substantial twist. Parts of Sheet B 
and C are arranged to form a barrel located on one end 
of the elliptical molecule. The barrel is made of 
strands 1, 2 and 3 of Sheet C and strands 1, 2, 3 and 4 
of Sheet B. 
The helices are concentrated in the N-terminal 
part of the linear sequence. Helices A to E are in 
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Fig.4: Poly peptide chain folding of human alpha-1-
proteinasn inhibitor. (Huber & Carrel 1 , 1989). 
Sccondarv structure el eraents are 
represented bv arrows 
c^'l in'lers fhplixes) and 
Table V. Residue numbers 
sr\'' the al i'^ ,nment in 
C-t'^ rminal to 358 have 
number in the plot. 
'Sheet Strands and 
marked according, to 
refer to alpha-1-PI 
Table V. Residues 
100 added to their 
16 
close proximity on one side of Sheet A. Residues 21 to 
147 may be regarded as a helix rich domain built from 
helix A, strand 6 of Sheet B, helices B to D, strand 2 
of Sheet A and helix E. Helix B is internal and 
characterised in the linear sequence by a long segment 
of apolar residues. Helix F leans on the opposite side 
of Sheet A, helices G and H are associated with the 
^ -barrel. 
Sheets 2A, 3A, 2B, 3B, 4B, 5B and 6B are buried 
and characterized by linear segments of apolar residues. 
Sheet B is largely buried in the interior of the 
molecule between Sheet A and helix rich domain. The 
charged residues form a shell around the hydrophobic 
core, though the distribution is not uniform. Lys and 
Arg are concentrated on the 'barrel' end of the 
ellipsoidal molecule while the acidic residues are more 
abundant on the opposite end. 
In the nicked species the new N and C termini 
conform to this arrangement : Ser-359 is located on the 
'barrel' side and Met-358 is on the opposite end. The 
molecule has substantial dipole moment. The conversion 
of virgin inhibitor to nicked species involves insertion 
or removal of strand 4A. 
The three carbohydrate attachment sites at Asn-46, 
Asn-83 and Asn-247 are all in bends of the polypeptide 
chain protruding from the surface of the molecule. Asn-
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46 is located in a segment between helix A and strand 
6B. Asn-83 is in the segment linking helices C and D, 
and Asn 247 is in the bend connecting 2B and 3B. 
The structure proposed for native inhibitor has 
the susceptible peptide bond near the barrel end of the 
molecule. Strand IB, a part of the barrel end, has the 
unique Cys-323 which is blocked presumably by cysteine 
or glutathione. Predicted (Gamier, et al., 1978) and 
observed secondary structures show a moderate 
correlation. In particular, strongly predicted helical 
regions agree with the observation. A remarkable 
exception is the region 325 to 355, which is strongly 
predicted as a helical region, but forms the central 
strand of Sheet A in the observed structure. Crystal 
structure studies have shown that cleaved and intact 
serpins differ essentially in the topology of Sheet A. 
This is five stranded in the intact molecules and six 
stranded after cleavage by insertion of strand 4A whose 
terminus has become free (Loebermann, et al., 1984; 
Wright & Huber, 1990) . 
In the intact native inhibitor the sequence Ala-
348-Ser-359 is plucked out to form strained loop whereas 
in the nicked inhibitor Met-358 is separated from Ser-
359 by a distance of 69A° (Loebermann, et al., 1984). 
Both the forms, i.e., strained (S) and relaxed (R) 
conformation, differ in thermal stability (Carrell & 
Owen, 1985), circular dichroism spectra (Bruch, et al., 
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1985), fluorescence spectral measurements (Bruch, et 
al. , 1985) and antigencity (Agostini & Carroll, 1985; 
Zhu & Chan, 1987). 
Reactive site loop (RSL) is an extended rigid loop 
that is complimentary to the substrate binding sites of 
a target proteinase. The RSL structure of the different 
classes of inhibitor is highly conserved despite the 
fact that the proteins themselves vary widely in overall 
structure (Laskowski & Kato, 1980; Read & James, 1986; 
Bode, et al., 1986; Hubbard, et al., 1991). 
The proposed structure of the RSL of virgin human 
alpha-1-PI is given in Fig. 5. It is because of the 
flexibility and movement of some of the upstream RSL 
residues in and out of Sheet A that the serpin RSL can 
be thought as a dynamic rather than a static structure 
(Mast, et al., 1992) . 
While insertion of RSL is not essential for 
protease binding, it is a necessary second step required 
for inhibitor function. The presence of a charged 
residue at P14 can retard this insertion resulting in 
conversion of the serpin to a substrate (Lawrence, et 
al. , 1994). A proposed model of serpin function 
suggests that the inhibitors have mobile RSL that can 
partially be inserted into Sheet A (Carrell, et al., 
1991; Carrell & Evans, 1992). However, further 
insertion yields a latent inhibitor that is no longer 
reactive with its target protease but has increased 
thermal stability (Mottonen, et al.,1992; Lomas, et al., 
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1995) . Blocking of loop insertion with synthetic loop 
peptides or by mutations within the loop converts the 
inhibitor into substrate (Carrell, et al.,1991; Schulze 
et al., 1990; Hood, et al., 1994). 
Mutations within the region P9-P15 of RSL result 
in loss of inhibitory activity (Huber & Carrell, 1989). 
However, mutations in this region can lead to polymer 
formation through insertion of the loop of one molecule 
into the B Sheet of another (Lomas, et al. , 1993; Mast, 
et al., 1992). This loop sheet polymerisation has 
provided an excellent explanation for the aggregation of 
the Z variant of human alpha-1-PI (Glu-342 to lys-342) 
in liver endoplasmic recticulum (Lomas, et al., 1992; 
Carrell, et al., 1994) . 
Despite the similarity of sequence, susceptibility 
to protease action, and presence of an elastase specific 
alanine at Pi position in the protease susceptible 
segment, ovalbumin is not an inhibitor of elastase but 
rather a good substrate for this enzyme (Wright, 1985). 
The reason for this was accounted for when the 
structure of plakalblumin (cleaved ovalbumin) and 
subsequently ovalbumin was shown (Stein, et al., 1990) 
which provided a model for uncleaved serpin (Wright, et 
al., 1990; Engh, et al., 1990) with 5 stranded pleated 
Sheet A bridged to -Sheet C by active site loop. All 
inhibitory serpins have a small residue (Thr, Ser, Ala 
or Val) at position 345 in strand 4A which is buried in 
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the cleaved species. Ovalbumin and its proteolytically 
modified form, plakalbumin, have an arginine in position 
345 which for stereochemical reasons cannot be internal. 
This was suggested as the main reason for the lack of 
conformation transition upon insertion of strand 4A into 
Sheet A (Wright, et al. , 1990; Schulze, et al. , 1990). 
The recently characterised recombinant alpha-1-PI, Thr-
345 --> Arg, Met-358 --> Arg variant (Schulze, et al., 
1991) is not an inhibitor and is similar to ovalbumin 
concerning denaturation, stability, demonstrating the 
key role of residue 345 for both inhibitory activity and 
rearrangement of Sheet A. 
Partial insertion of strand 4A is necessary for 
inhibitory conformation of the binding loop. A bulky 
residue at position 345 prevents this and renders the 
inhibitor into a substrate. The loop adopts an (X -
helical conformation in intact ovalbumin (Stein, et al., 
1990), not competent for proteinase binding (Bode & 
Huber, 1991) . It has been suggested also that active 
serpin inhibitors have an -helical loop which uncoils 
prior to or during proteinase attachment accompanied by 
insertion of strand 4A into Sheet A up to residue 349 
(Skriver, et al., 1991). 
Residues and interactions involved in complex formation 
between alpha-1-PI and serine proteinases 
The interaction between alpha-1-PI and serine 
proteinases is very strong. The serine residue of the 
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proteinases contributes substantially towards the 
interaction. The inhibitor-enzyme complex is further 
stabilized by ionic and hydrophobic interactions. Thus 
the increase in temperature and ionic strength greatly 
enhance the inhibitor and enzyme complex (Saklatvala, et 
al., 1976; Satoh, et al., 1979). Moreover, the complex 
formation is found to be blocked by 20% dioxane (Cohen, 
1975) . The inhibitor on its reaction with maleic 
anhydride (Heimberger, et al., 1971), acetic anhydride 
(Fretz & Gan, 1978) or citraconic anhydride (Johnson & 
Travis, 1975), all of which react with lysyl residues in 
proteins, inactivated the inhibitor towards trypsin, 
chymotrypsin and elastase suggesting the involvement of 
lysine and arginine residues of alpha-1-PI in the 
complex formation between the inhibitor and its cognate 
enzyme. However, chemical modification of lysyl 
residues in proteins that alters the charge on the 
protein molecule or introduces a bulky group, is known 
to disrupt protein conformation (Ansari, et al., 1975, 
Qasim & Salahuddin, 1978) . Accordingly, when less bulky 
group was introduced at the lysyl residues of alpha-1-PI 
without affecting its net charge, this chemical 
modification did not result in inactivation of the 
inhibitor (Busby, et al. , 1977), and excluded the 
possibility of involvement of lysine residue of the 
inhibitor in complex formation. It has also been 
suggested that arginine (Cohen, 1973) and tyrosine 
(Feste & Gan, 1981) residues of alpha-1-PI might be 
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involved in its inhibitory activity. 
Role of methionine residues in the inhibitory activity 
of alpha-1-PI 
There are several lines of evidence which suggest 
the involvement of methionine residues of the inhibitor 
in its inhibitory activity (Janoff & Carp, 1977; Johnson 
Sc Travis, 1978, 1979; Carp & Janoff, 1979; Ohlsson, et 
al, 1980; Abrams, et al., 1981a). Oxidation of 
methionine residue, at positions PI and P8 and also 
other few methionine residues, to methionine sulphoxide 
by the release of oxidants by neutrophil elastase during 
phagocytosis lead to the inactivation of the alpha-l-PI 
(Carp & Janoff, 1979) . Substantial loss in thfe 
inhibitory activity of alpha-l-PI towards neutrophil and 
pancreatic elastases by unfractionated cigarette smoke 
(Janoff & Carp, 1977; Ohlsson, et al. , 1980; Abrams, et 
al., 1981a) was prevented by antioxidants. 
The inhibitory activity of the oxidised alpha-l-PI 
can be restored by methionine sulphoxide reductase 
(Abrams, et al., 1981b). This enzyme is likely to play 
a role in preventing unwanted tissue proteolysis in 
lung. Oxidation of methionine to methionine sulphoxide 
causes reduction in the interaction of alpha-l-PI with 
target enzyme presumably because of steric hindrance 
offered by the relatively bulky methionine sulphoxide at 
the reactive site (Loebermann, et al., 1984). If the 
24 
methionine at 358 position in the alpha-1-PI is mutated 
to valine then it was found that the Val mutant of 
alpha-1-PI was not inactivated upon oxidation as 
compared to the normal alpha-1-PI which did not react 
with pancreatic elastase upon oxidation (Rosenberg, et 
al., 1984). 
Nature has provided such a vulnerable reactive 
centre for alpha-1-PI as to effect the ability to switch 
off alpha-1-PI which provides a means by which essential 
tissue breakdown can occur in the immediate vicinity of 
an inflammatory focus (Carrell, et al. , 1982) and 
perhaps in the area of regrowth. 
Biological significance of alpha-1-PI 
Abnormal phenotypes of alpha-1-PI have been 
associated with a number of diseases including lung 
diseases, like eymphysema, (Lieberman, 1976), 
bronchietasis (Shin & Hn, 1993), pneumonia (Braun, et 
al. , 1994), liver diseases like obstructive jaundice, 
fatal juvenile cirrhosis (Propst, et al. , 1994), 
rheumatoid arthiritis (Zhang, et al., 1993; Chidwick, et 
al., 1994) and hepatocellular carcinoma (Scott, 1994). 
Alpha-1-PI has been reported to be involved in the 
pathogenesis of the lesions of Alzheimer's disease 
(Gollin, et al., 1992). Alpha-1-PI phenotypes of Ml, 
M2, M1M2, M2M3, M1M3 were found in patients with 
Behcet's disease (Fakuda, 1992). 
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Alpha-1-PI can be proteolytically inactivated by 
several matrix metalloproteinases including interstitial 
collagenase, stromelysin, gelatinase and matrilysin 
(Ottonello Sc Dapino, 1993; Zhang, et al. , 1994; Sires, 
at al. , 1994). Reactive oxygen species in cigarette 
smoke (Travis & Salvesen, 1983) and coal dust (Huang & 
Laurent, 1993) leads to inactivation of alpha-1-PI. It 
has been reported that glutathione has protective role 
in alpha-1-PI inactivation by myeloperoxidase system of 
activated phagocytic cells in case of emphysema 
(Gressier, et al., 1994). 
A review of literature mentioned above 
demonstrates an emphasis on the inactivation of alpha-l-
PI primarily by oxidative modification of the critical 
methionine residue in the inhibitor. The inhibitor is 
known to undergo inactivation at extreme pH values in 
the acidic and alkaline range. In this dissertation we 
have focused our attention primarily on the alkaline 
inactivation of alpha-1-PI. Our results have shown that 
the inhibitor was fairly stable in the pH range 5-10, 
beyond which increase in pH caused irreversible 
inactivation of alpha-1-PI. 
Sxft^nimetit^ 
EXPERIMENTAL 
A. MATERIALS 
1. Proteins 
Bovine serum albumin (Lot no lOOF-0249), ovalbumin 
(Lot no. 105C-8022), chymotrypsinogen A (Lot no.40F-
8050), cytochrome c (Lot no. 09C-0088), myoglobin (Lot 
no. 85C-0138), bovine trypsin type III (Lot no.l28F-
0397) were purchased from Sigma Chemical Company, St. 
Louis, MO., USA. 
2. Substrate for assay of proteolytic enzyme 
Alpha-N-benzoyl-DL-arginine-p-nitro-anilide 
(BAPNA) (Lot no. 37F-0833) which was used in the assay 
of trypsin was obtained from Sigma Chemical Company, St. 
Louis, MO., USA. 
3 . Column chromatographic media 
Diethylaminoethyl cellulose (DEAE-cellulose) (lot 
no. F/8/6011) was obtained from Sisco.Res.Lab. Bombay, 
India. Sephadex G-lOO, Blue Dextran 2 000 were purchased 
from Pharmacia Fine Chemicals, Uppsala, Sweden. Con A 
Sepharose 4B (Lot no. 90C-0495) was obtained from Sigma 
Chemical Company, St. Louis, MO., USA. 
4. Reagents used for gel electrophoresis 
Reagents used in eletrophoresis with their sources 
in parantheses were : acrylamide (E. Merck, Dramstadt, 
Germany),N~N'-methylene bisacrylamide (Reanal, Budapest, 
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Hungary), N, N, N ' , N ' - t e t r a m e t h y l e t h y l e n e d i a m i n e (Ferak, 
B e r l i n , Germany) , 2 - m e r c a p t o e t h a n o l (BDH,Poole, 
Eng l and ) , ammonium p e r s u l p h a t e (E. Merck, D r a m s t a d t , 
Germany), sodium dodecyl su lphate (BDH, Bombay, I n d i a ) , 
coomassie b r i l l a n t b lue R-250 (Sigma Chemical Company, 
S t . Louis, MO., USA), and d i - ch lo rod ime thy l s i l a n e (BDH, 
Poole , England) . G l y c e r o l was o b t a i n e d from BDH, 
Bombay, I n d i a . 
5. Miscellaneous reagents 
Methanol, a c e t i c ac id , glucose and chloroform were 
purchased from BDH, Bombay, Ind ia . T r i s (hydroxymethyl) 
amino methane was o b t a i n e d from S i s c o , R e s . L a b . , 
Bombay, I n d i a . Sodium azide was o b t a i n e d from Fluka, 
Switzer land and dimethyl sulphoxide was purchased from 
BDH, Poole, England. The r e s t of t he chemica ls used were 
of a n a l y t i c a l g r ade . Glass d i s t i l l e d wa te r was used 
throughout t h e s e s t u d i e s . 
B. METHODS 
1. Measurement of pH 
E l i c o d i g i t a l pH meter model LI-122, was used for 
pH measurements i n c o n j u n c t i o n w i t h E l i c o combined 
e l e c t r o d e a t room t e m p e r a t u r e . The pH m e t e r was 
s t a n d a r d i z e d w i t h 0.05M p o t a s s i u m h y d r o g e n p t h a l a t e 
buffer , pH 4.0 i n t h e a c i d i c range and w i th O.OIM sodium 
t e t r a b o r a t e bu f f e r , pH 9.2 i n the b a s i c r a n g e . 
2. Optical measurements 
Absorbance in the visible range was measured on a 
AIMIL photochem-8 colorimeter. In the ultraviolet 
region, light absorption measurements were performed on 
Cecil UV-double beam spectrophotometer, model CE-594 
using silica cells of 1 cm path length. 
The CD spectra were measured on a Jasco 
Spectropolarimeter model J-720 instrument, using a 
Sekonic X-Y plotter (model SPL-430A) and PC-A T286 
compatible computer with 1024 Kb Ram. The pathlength of 
cell used was 0.1 cm. 
The mean residue ellipticity ( 6 )^  , 
(6), = A^ 
10 X n X Cp X L 
where 
6> = ellipticity in mdeg at a given wavelength, 
n = number of amino acid residues in the 
protein, 
Cp = molar concentration of the protein, and 
L = path length of the cell in cm. 
3. Determination of protein concentration 
Protein concentration was determined either by the 
method of Lowry, et al. (1951) or by spectrophotometric 
method. 
(a) Lowry's method 
To one ml of protein solution was added 5 ml of 
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copper reagant and after mixing the solution, it was 
allowed to stand for 10 minutes at room temperature. 
Then 1 ml of Folin-phenol reagant was added to the 
mixture and the contents were mixed well. The mixture 
was incubated for 30 minutes and the colour intensity-
was read at 700 nm. A calibration curve between optical 
density at 700 nm and protein concentration in milligram 
was obtained by the method of least squares (Fig. 6) , 
using bovine serum albumin as standard. The linear 
curve was found to fit the equation : 
(Absorbance) 7QQj^ j^  =1.67 (mg, protein) + 0.009 (1) 
(b) Spectrophotometric method 
In a few experiments, the protein concentration 
was determined by measuring the optical density of 
protein solution in 0.1 M Tris-HCl buffer, pH 8.0 
containing 0.15M NaCl, ImM CaCl2, MnCl2 and MgSO^ using 
appropriate values of specific extinction coefficient, 
"^""^ icm ^^ ^^'^ ""^- "^ ^^  values of E^^^^^ used were : 
trypsin, 14.4 (Walsh, 1970) and alpha-1-PI, 5.3 (Pannell 
& Travis, 1974). 
4. Chromatography 
(a) Ion exchange chromatography 
Alpha-1-PI was purified by DEAE-cellulose 
chromatography. In order to regenerate the resin, it 
was treated with one litre of 0.1 M sodium hydroxide and 
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Protein concentration , mg . 
Fig. 6 : Calibration curve for Che estimation of protein 
concentration by the method of Lowry, et a]., (1951) 
Bovine serum albumin was used as the standard'protein' 
The straight line drawn by the method of least 
follows the equation: squares 
(Absorbance'. 700 1.67 img, protein) n.009 
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then washed extensively with distilled water till pH of 
the washing became neutral. After this, the ion 
exchanger was treated with one litre of O.l M 
hydrochloric acid and washed extensively with water till 
pH of the washing became neutral. The exchanger was 
packed into a column (2.5 X 5.8 cm) and subsequently 
equilibrated with 10 mM sodium phosphate buffer, pH 7.6. 
(b) Affinity Chromatography 
Con A Sepharose 4B gel was packed into a glass 
column (2.2 X 5.3 cm) and was subsequently equilibrated 
with the operating 10 mM Tris-HCl buffer pH 7.6, 
containing 0.15 M NaCl, ImM CaCl2, MnCl2 and MgSo^. The 
inhibitor was further purified on this affinity matrix. 
(C) Sephadex gel chromatography 
The alpha-1-PI was isolated on a Sephadex G-lOO 
column (2.4 X 79 cm) which was packed according to the 
method of Ansari and Salahuddin (1973). The homogeneity 
of packing was checked by passing a band of 0.02% (w/v) 
solution of Blue Dextran through the column. The 
pattern of the elution profile showed uniform packing of 
the column. The elution volume (Ve) of Blue Dextran 
yielded the void volume (Vo) of the column. As can be 
seen in Fig.7 the dye eluted from the column as a 
symmetrical peak with an elution volume of 135 ml. The 
total volume of the column, V^, was determined to be 358 
ml. The column was equilibrated with lOmM sodium 
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Fig. 7: Gel rhronatography of Blue Dextran on Sephadex 
G-lOO column. 
About 10 ng of the sample was applied to the 
column (2.4 x 79 cm) equilibrated with 10 mM sodium 
phosphate buffer, pH 706 and eluted in 5 ml 
fractions at a flow rate of 20 ml/hr. The colour 
intensity was read at 610 nm. 
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phosphate buffer, pH 7.6 containing 0.02% (w/v) sodium 
azide and operated at a flow rate of 30 ml/hr. 
5. Sodium dodecyl sulphate polyacrylamide gel 
electrophoresis 
Sodium dodecyl sulphate polyacrylamide tube gel 
electrophoresis was carried out by a method essentially 
due to Laemmli (1970) . For the preparation of small 
pore gel (12.5% cross-1inking), 7.5 ml of 30% acrylamide 
solution, 0.8% N-N'-methylene bisacrylamide, 0.01 ml of 
N,N,N',N' tetramethylethylenediamine tetra acetic acid 
and 0.07 ml of 10% ammonium persulphate were mixed. 
Sodium dodecyl sulphate (0.1%) was also present in the 
gel. A drop of water was carefully applied on top of 
the gel and it was left to polymerize for some time. 
Stacking gel (2% cross linking) was layered on top of 
the small pore gel and a drop of water was carefully 
layered over it as before. 
For the preparation of sample, the protein was 
dialyzed against 0.025M Tris, 0.192 M glycine buffer, pH 
8.3 containing 0.1% SDS. Then the sample was heated for 
30 minutes in a boiling water bath. After cooling the 
sample, few drops of glycerol containing 0.1% (w/v) 
bromophenol blue were added. The sample was reduced by 
adding O.IM 2-mercaptoethanol. An appropriate volume 
of this mixture (0.05 - 0.1 ml) containing 60-80 ug of 
protein was then applied to the gel tubes. The 
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electrophoresis was carried out for 6-7 hours in 0.025M 
Tris, 0.192 M glycine, buffer pH 8.3 using a current of 
6 mA per tube. The gels were removed from the gel tubes 
with the help of a long needle attached to a syringe. 
These were then stained with 0.2% (w/v) coomassie 
brilliant blue R-250 dye in 25% (v/v) methanol and 10% 
(v/v) acetic acid and destained mechanically with 10% 
(v/v) acetic acid. The relative mobility (Rm) of the 
proteins were calculated by the standard procedure. 
6. Determination of inhibitory activity 
The inhibitory activity of alpha-1-PI was measured 
against trypsin. The substrate used for trypsin was 
BAPNA. The enzyme induced hydrolysis of BAPNA produced 
p- nitroanilide(pNA) which absorbed maximally at 410 nm. 
The absorbance at 410 nm was taken to represent the 
concentration of hydrolyzed product. A fixed concen-
tration of enzyme was incubated with different 
concentrations of alpha-1-PI in 0.1 M Tris-HCl buffer, 
pH 8.0 containing 0.01 M CaCl2 for 30 minutes at 37°C. 
The residual enzyme activity for trypsin catalyzed 
hydrolysis of BAPNA was measured as described by 
Erlanger, et al., (1961). The final concentration of 
BAPNA taken for the reaction was 0.8 mM. 
7. Isolation and purification of alpha-1-PI 
Alpha-1-PI was isolated from discarded human 
plasma by modifying the method described by Musiani and 
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Tomasi (1976) . The serum was p r e c i p i t a t e d with an equal 
volume of s a t u r a t e d ammonium s u l p h a t e . The p r e c i p i t a t e 
thus o b t a i n e d was d iscarded and the superna tan t was 
f u r t h e r s u b j e c t e d t o 80% ammonium s u l p h a t e 
c o n c e n t r a t i o n . The 80% (NH4)2S04 p r e c i p i t a t e t h u s 
o b t a i n e d by c e n t r i f u g a t i o n was d i a l y z e d e x t e n s i v e l y 
a g a i n s t lOmM sodium phosphate bu f f e r , pH 7 . 6 . The crude 
i n h i b i t o r was f u r t h e r p u r i f i e d by i on exchange 
chromatography on DEAE-cellulose column (2.5 X 5.8 cm) 
e q u i l i b r a t e d wi th lOmM sodium phosphate bu f fe r , pH 7 .6 . 
The p r o t e i n was e l u t e d b a t c h w i s e w i t h lOmM sodium 
phosphate bu f f e r , pH 7.6 con t a in ing 0.05 M, 0 .1 M, 0.15 
M and 0.2 M NaCl. The f r a c t i o n s con ta in ing a lpha-1-PI 
l o c a t e d u s i n g BAPNA as s u b s t r a t e for t r y p s i n were pooled 
and c o n c e n t r a t e d by (NH4)2S04 p r e c i p i t a t i o n . The 
i n h i b i t o r was f u r t h e r p u r i f i e d by e x t e n s i v e l y d i a l y z i n g 
t h e p r e c i p i t a t e aga ins t 10 mM Tr i s -Hc l buf fe r pH 7.6 , 
c o n t a i n i n g 0.15 M NaCl, ImM CaCl2, MnCl2 and MgSO^ and 
app ly ing on concanval in A bound Sepharose 4B column (2.2 
X 5.3 cm) . The unbound m a t e r i a l was e l u t e d with 10 mM 
Tris-HCl bu f f e r , pH 7.6 con t a in ing 0.15M NaCl, 1 mM 
CaCl2, MnCl2 and MgSO^ and a lpha -1 -P I was subsequent ly 
e l u t e d wi th 0.5 M glucose in the same b u f f e r . The 
f r a c t i o n s showing a n t i t r y p t i c a c t i v i t y were p o o l e d , 
c o n c e n t r a t e d and chromatographed on Sephadex G-lOO 
column (2.4 X 79 cm) in lOmM sodium phosphate buf fe r , pH 
7 . 6 . The a l p h a - 1 - P I f r a c t i o n s were p o o l e d and 
c o n c e n t r a t e d . 
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RESULTS AND DISCUSSION 
A. Isolat ion, purification and molecular weight of 
alpha-1-PI 
A l p h a - 1 - p r o t e i n a s e i n h i b i t o r was i s o l a t e d from 
human plasma by s a l t f r a c t i o n a t i o n fol lowed by ion 
exchange chromatography and chromatography on Con A 
Sepharose 4B. The r e su l t s are summarised in Table VI. 
S t a r t i n g from 500 ml of plasma c o n t a i n i n g 30.965 gm 
p r o t e i n , 2.310 gm crude i n h i b i t o r was i s o l a t e d by 
ammonium sulphate f ract ionat ion. I t was purif ied by 
chromatography on DEAE-cellulose column e q u i l i b r a t e d 
with 10 mM sodium phosphate buffer, pH 7.6 . The protein 
was e l u t e d ba tchwise with sodium phosphate buffer 
containing increasing NaCl (0.05-0.2M). Four peaks were 
obtained out of which fractions under peak C showed 
a n t i t r y p t i c a c t i v i t y using BAPNA as s u b s t r a t e {see 
F i g . 8 ) . Ion exchange chromatography r e s u l t e d in 
s i g n i f i c a n t p u r i f i c a t i o n of p r o t e i n . However the 
p u r i f i e d i n h i b i t o r contained s i g n i f i c a n t amount of 
impurity. Consequently, when protein was passed on Con A 
Sepharose 4B column equil ibrated with metal l ized Tris 
buffer, pH 7.6, the inhibi tor being glycoprotein was 
spec i f i ca l ly bound to column. Elution with operating 
buffer gave a s ingle wash through peak and about 160 mg 
of pro te in was spec i f i ca l ly eluted with 0.5 M glucose. 
The a c t i v i t y was located only in f rac t ions speci f ica l ly 
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TABLE VI 
PROTEIN YIELD AT VARIOUS STAGES OF PURIFICATION OF HUMAN 
ALPHA-1-PROTEINASE INHIBITOR 
Step Total Total Fold Percent 
protein specific purifi- reco-
(mg) activity* cation very 
Plasma 
50-80% (l^^) 2 SO4 
fraction 
Ion exchange chromato-
30965 
2130 
1129 
500 
75.6 
70 
1 
2.2 
3.8 
6.9% 
3.6% 
graphy on DEAE cellulose 
Affinity chromatography 160 58 22.3 0.5% 
on Con A Sepharose 4B 
Gel filtration on 125 53 26.3 0.4% 
Sephadex G-lOO 
*1 specific unit is defined as amount of inhibitor required 
for complete inhibition of 1 mg of trypsin. 
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40 eO 120 160 200 240 
Elution volumt, ml. 
2S0 320 
Fig. 8: Ion exchanoo chromato^r^ohy of salt fractionated 
crudo human J^ oha-l-oroteinase inhibitor on DEAE-
ce) lul ose col u-^ n . 
Drotein in 
7.6 
About '^5 -TO of 
sodiu- ohosphate' buffer, pH 
ni:AF-cpl lulose colunn {2.5 x 
Kith opnratin'^ buffer. The 
batch\:ise with 0.05^ 1, O.IM, 
n.2'1 NaCl in th'? buffc^ r in 5 
20 "1/h 
5 1^ of 10 nri 
was applied to 
S.^ en) euuilibra ted 
nrotein was eluted 
0.15M and 0.2^ and 
nl fractions at flow 
rate or 20^1/hr. The nrotein concentration was 
determined bv the nethod of Lowrv, et al. , (1951) 
The antitrvotic activity was located in oeak C 
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eluted with 0.5 M glucose. Protein fractions under peak 
B of Fig. 9 were pooled and gel filtered on Sephadex G-
100 column equilibrated with lOmM sodium phosphate 
buffer, pH 7.6, a single protein peak was obtained. This 
suggested the size homogeneity of alpha-1-PI. Finally, 
125 mg of size homogeneous alpha-1-PI was obtained from 
500 ml of human plasma. 
SDS-PAGE of the purified alpha-1-PI in 12.5% 
cross-linked gel at pH 8.3 yielded a single coomassie 
stainable protein band under reducing and non reducing 
conditions (see Fig.10). The marker proteins, namely 
bovine serum albumin, ovalbumin, chymotrypsinogen A, 
cytochrome c. were electrophoresed under identical 
conditions. The relative mobilities of marker proteins 
and alpha-1-PI are listed in Table VII. A plot of log M 
versus Rm was obtained by method of least squares and is 
given in Fig. 11; the curve fits the equation: 
Log M = 5.182 - 1.204 Rm (2) 
Corresponding to Rm of 0.36, the molecular weight of 
alpha-1-PI was computed with the help of equation (2) to 
be 56,000. The latter is only 9.8% higher than the 
literature value of 51,000. 
The elution profile of the inhibitor on Sephadex 
G-lOO is shown in Fig.12. Marker proteins namely bovine 
serum albumin, ovalbumin, chymotrypsinogen A, myoglobin, 
and cytochrome c were passed through the column under 
identical conditions and the results are graphically 
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F i g . 9: Chromatography of human a ] p h a - 1 - p r o t e i n a s e 
on Con A Sepharose 4B column. 
inhibitor 
About 
meta] 1 ised 
column (2 
alone at 
fractions 
70 mg of protein in 5 ml of 10 mM 
Tris-HCl buffer, pH 7.6 was applied on the 
2 X 5.3 cm) and eluted with the buffer 
a flow rate of 5 ml/hr. The protein 
in wash through peak A was devoid of 
antitryptic activity. The protein fractions under 
peak B were obtained by specific elution of 
glycoprotein with 0.5 M glucose in operating buffer 
at a flow rate of 30 ml/hr. The column was monitored 
by the method of Lowry, et al . , (1951). The 
antitryptic activity was locoated in fractions under 
peak B. 
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Fig. 10: Sodium dodecy] sulphate polyacrylamide ge] 
e]ectrophonetlc pattern of human alpha-1-
protelnase Inhibitor. 
About 60 ug of inhibitor was 
electrophoresed in 0.025 M Trls 0.192 M 
glycine buffer, pH 8.3 containing 0.17o SDS 
in 12.5"'- polyacry] amide gel for 6 hours at 
6 mA current flow per tube. The gel was 
stained with 0.27o coomassic brilliant blue 
R-2'iO and destained mechanically with 107o 
(V/V) acetic acid as described in the 
'Experimental Section'. 
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TABLE VII 
MOLECULAR NEI6HTS AND RELATIVE MOBILITIES OF MARKER PROTEINS 
USED IN SODIUM DODECYL SULPHATE POLYACRYLAHIDE 
GEL ELECTROPHORESIS 
S.No. Protein Molecular Log M. Rm 
weight* 
1. Bovine serum 68,000 4.83 0.30 
albumin 
2. Ovalbumin 43,000 4.63 0.44 
3. Chymotrypsinogen A 25,700 4.44 0.63 
4. Cytochrome c 11,700 4.07 0.92 
5. Alpha-1-PI -- -- 0.36 
a. Weber and Osborn (1969). 
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o 
R m 
F i g . 1 1 : P]ot of Rm values of marker p r o t e i n versus 
logar i thm of molecular weight . 
The marker p r o t e i n s were (1) bovine 
serum albumin (2) ovalbumin (3) 
chymotrypsinogen A (4) cytochrome c . The Rm 
va lue of alpha-1-PI i s i n d i c a t e d by an arrow. 
The s t r a i g h t l i n e obta ined by the method of 
l e a s t squares f i t s the equa t i on : 
Log M = 5.182 - 1.204 Rm 
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180 190 200 
Elution volume j ml 
220 
F i g . 12: Gel chromatography of pur i f i ed human a l p h a - 1 -
pro te inase i n h i b i t o r on Sephadex G-lOO column. 
About 15 mg of i n h i b i t o r was appl ied to the 
column (2 .4 x 79 cm) e q u i l i b r a t e d with 10 mM sodium 
phosphate b u f f e r , pH 7 .6 . The p ro t e in was e l u t e d in 
3 ml f r a c t i o n s at a flow r a t e of 20 m l / h r . The 
pro te in was monitored by the method of Lowry, e t al . , 
(1951). 
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shown in Figs. 13, 14, 15, 16, 17. The elution volume 
of Blue Dextran from the column was determined to be 
135ml (see Fig.7) The Ve/Vo of marker proteins as well 
as alpha-1-PI are summarised in Table VIII. Analysis of 
the results by least square method yielded a straight 
line (see Fig.18) which fits the equation: 
Ve/Vo = -0.589(log M) + 4.239 (3) 
The ratio of Ve/Vo for alpha-1-PI was found to be 
1.42 which according to equation (3) corresponds to 
molecular weight of 60,000, which is significantly 
higher than the reported value of 51,000. This 
discrepancy is understandable in view of the fact that 
alpha-1-PI is a glycoprotein containing 13% 
carbohydrate. Since elution volume of a protein in gel 
chromatography correlates better with its Stokes radius 
(Ackers, 1970), it is expected to be higher for proteins 
showing marked degree of hydration. Glycoproteins 
usually bind more water than non glycoproteins, this 
generally causes an over-estimation of the molecular 
weight of glycoproteins by gel filtration. However, the 
molecular weight values determined by gel filtration and 
SDS-PAGE are comparable, not identical. These results, 
taken together, suggest that alpha-1-PI consists of a 
single polypeptide. 
B. Alkaline inactivation of alpha-1-PI 
The purified alpha-1-PI was sensitive to pH at 
extreme pH values. Below pH 5.0, the inhibitor was less 
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F i g . 13; 
110 130 150 170 190 210 
Etution volume , ml. 
Gel chromatography of bovine serum albumin on 
Sephadex G-lOO column. 
About 10 mg pro te in was appl ied to the 
column (2.4 x 79 cm) e q u i l i b r a t e d with lOmM 
sodium phosphate buffer , pH 7 .6 . The p r o t e i n was 
e l u t e d in 5 ml f rac t ions at a flow r a t e of 
20 ml /h r . The column was monitored by the method 
of Lowry, e t a l . , (1951). 
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150 200 
Elution volume , ml 
250 
Fig. 14: Ge] chromatography of ovalbumin on Sephadex 
G-lOO column. 
Experimental conditions were the same as 
given in the legend to Fig. 13. 
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170 180 210 230 250 
Elution volume j ml. 
270 
Fig. 15: Gel chromatography of chymotrypsinogen A on 
Sephadex G-lOO column. 
Experimental conditions were the same 
given in the legend to Fig. 13. as 
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190 220 250 
Elution volume ; ml. 
280 
F i g . 16:Ge] chromatography of myoglobin on Sephadex G-lOO 
Co] utnn. 
Experimental cond i t ions were the same as given 
in the legend to F ig . 13. 
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Fig. 17: Ge] chromatography of cytochrome c on 
Sephadex G-lOO co]umn. ~ 
Experinenta] conditions were the same 
as given in the legend to Fig. 13. 
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TABLE VIII 
GEL FILTRATION DATA FOR THE MARKER PROTEINS OBTAINED ON 
SEPHADEX G-lOO COLUMN 
S.No. Protein Molecular Log M Ve(ml) Ve/Vo 
weight^ 
1. 
2. 
3. 
4. 
5. 
6. 
Bovine serum 
albumin 
Ovalbumin 
Chymotrypsinogen A 
Myoglobin 
Cytochrome c 
Alpha-1-PI 
68,000 
43,000 
25,700 
17,200 
11,700 
4.83 
4.63 
4.44 
4.23 
4.07 
185 
200 
230 
235 
245 
192 
1.37 
1.53 
1.7 
1.74 
1.81 
1.42 
a. Weber and Osborn (1969). 
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(og M 
F i g . 18:P]ot of Ve /V -^ values of marker p r o t e i n s versus 
logar i thm of molecular weight . 
The marker p r o t e i n s were (1) bovine serum 
albuirdn (2) ovalbumin (3) chymotrypsinogen A 
(4) myoglobin (5) cytochrome £ . The Vg/Vo value 
of a lpha-1-PI i s i n d i c a t e d by an arrow. The 
s t r a i g h t l i n e computed by the he lp of l e a s t 
s q u a r e s , f i t s the equa t ion : 
V /V 
e o 0.589 (Log M) + 4.239 
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soluble and was completely precipitated from the aqueous 
solution at pH 2.0. The precipitate dissolved in 8 M 
urea. However, after replacement of urea with lOmM 
sodium phosphate buffer pH 7.6, the inhibitory activity 
could not be restored. The inhibitor showed activity in 
the pH range 5.0 - 10.0. Above pH 10.0, it underwent 
inactivation. We report below the results on the time 
course of inactivation of alpha-1-PI at pH 11.0 at four 
temperatures namely 25°C, 30°C, 35°C, and 40°C. The 
buffer used was lOmM sodium carbonate buffer, pH 11.0 
containing 0.15M NaCl. 
First, alpha-1-PI (1 ml, containing 2.4 mg 
protein) was mixed with 4 ml of 10 mM sodium carbonate 
buffer, pH 11.0 and incubated at a given temperature for 
various lengths of time. Aliquots of 0.1ml of the 
inhibitor solution were taken and their pH was adjused 
to 7.6. To this mixture was added 0.1ml of trypsin 
(containing 0.1 mg protein) in lOmM sodium phosphate 
buffer, pH 7.6 and the residual tryptic activity was 
measured against BAPNA. The percent inhibition of 
tryptic activity, was measured as described in the 
'Experimental Section'. A plot of percent inhibition 
versus time in hours was obtained at four different 
temperatures. The results are graphically shown in 
Fig.19. 
The results of Fig.19 were analysed according to 
first order kinetics law in the form of a plot between 
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Time o"f incubation , hrs . 
Fig. 19: Time course of the alkaline inactivation of human alpha-1-
proteinase inhibitor at different temperatures. 
One ml of inhibitor solution containing 2.4 mg of 
protein was mixed with 4 ml of 10 mM sodium carbonate 
buffer, pH 11.0, and incubated at 25°C (4^ -« ) , 30°C (•-•), 
35°C (O-O ) and 40°C (4-^). Aliquots of 0.1 ml were taken 
at different time intervals and assayed for antitryptic 
activity as described in the 'Experimental Section'. 
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log percent inhibition and time. The slope of the 
straight line at 25°C was found to be 2.28 x 10"-^  whence 
the rate constant k, for the inactivation of alpha-1-PI 
was computed to be 2.28 x 10"^. By similar procedure 
the rate constants at three other temperatures, viz., 
30°C, 35°C, 40°C were computed. The values of k at 
different temperatures are summarised in Table IX. 
Arrhenius plot between Ink and l/T was obtained by the 
method of least squares. The slope of the straight line 
shown in Fig.20 was determined to be - 9430.82. The 
activation energy calculated from the slope comes out to 
be 18.74 kcal / mole or 78.4 kJ/mole. The value of 
18.74 kcal/mole is considerably lower than the 
activation energy determined for denaturation of 
proteins. Cathepsin B undergoes alkaline denaturation 
which is accompanied by large structural changes. 
(Turk, et al. , 1994). The activation energy for 
the denaturation of Cathepsin B was measured to be 44 
kcal/mole. This value is obviously much higher than 
that found for alkaline inactivation of alpha-1-PI in 
this study. Our results on circular dichroism spectra 
of alpha-1-PI in the UV region (200-250 nm) (Fig.21) 
show that the extent of secondary structure is the same 
at pH 8.0 and pH 11.0, although the inhibitor exhibits 
activity at pH 8.0 and is devoid of activity at pH 11.0. 
Thus, alkaline inactivation of alpha-1-PI does not 
appear to be accompanied by major conformational 
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TABLE IX 
FIRST ORDER RATE CONSTANT FOR THE ALKAJLINE INACTIVATION 
OF ALPHA-1-PROTEINASE INHIBITOR AT DIFFERENT 
TEMPERATURES 
S.No. Temperature Rate Constant 
(min"^) 
1. 25°C 2.28xlO~3 
2. 30°C 6.0x10"^ 
3. 35°C 6.65x10"^ 
4. 40°C 12.28x10"^ 
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C 
3.1 3.2 3.3 3.4 
I / T { d e g K X 1 0 ' ^ ) 
Fig . 20: Arrhenius p lo t for the a l k a l i n e i n a c t i v a t i o n 
of hu-an a lpha -1 -p ro t e ina se i n h i b i t o r . 
A l i n e a r p lot between In k versus l / l 
was obta ined by method of l e a s t s q u a r e s . The 
s lope of t h i s l i n e was found t o be -9430.82 
which y ie lded a value of 18.74 kzal/ipole for 
a c t i v a t i o n energy of the a lka l i ne 
i n a c t i v a t i o n of a lpha -1 -P I . 
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Fig.21 : Circular dichoroistn spectra of human alpha-
1-proteinase inhibitor. 
The far ultraviolet CD spectra of 
alpha-1-PI (0.22 mg/ml ) was carried out at 
pH 8.0 ( t—>) in 10 iT,M sodium phosphate 
buffer containing 0.1 M NaCl and at pH 11.0 
(,„._) in 10 mM sodium carbonate buffer 
containing 0.1 M NaCl. The spectra was 
recorded at 20°C. 
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changes. It is conceivable that exposure of inhibitor 
to alkaline pH produces small perturbation which does 
not significantly affect the secondary structure on the 
whole. Alternatively, the inactivation may be the 
result of changes in the tertiary conformation of the 
protein. 
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